Oramed Pharmaceuticals Inc. — Director's Dealing 2022

Feb 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2022-02-17

Reporting Person: RAKIN KEVIN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-17	Common Stock	M	6667	$4.80	Acquired	59671	Direct
2022-02-17	Common Stock	F	3010	$10.63	Disposed	56661	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-17	Stock Option (right to buy)	$4.80	M	6667	Disposed	2030-01-08	Common Stock (6667)	Direct

Footnotes

F1: Represents a cashless exercise of outstanding stock options to purchase 6,667 shares of common stock. The reporting person received 3,657 shares of common stock and surrendered 3,010 shares of common stock underlying the stock option in payment of the exercise price.